Rebecca Markovich - 17 Jul 2023 Form 4 Insider Report for Talis Biomedical Corp

Reporting relationship: Interim CFO
Issuer ticker: N/A
Reported as of: 17 Jul 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Jul 2023, 17:37:27 UTC
Prior SEC filing: 25 Apr 2023
Source filing: View source filing
Reporting owner signature: /s/ Gillian Green, Attorney-in-fact for Rebecca Markovich

Key filing fact

Rebecca Markovich filed Form 4 for Talis Biomedical Corp on 18 Jul 2023.

Key facts

This page summarizes Rebecca Markovich's Form 4 filing for Talis Biomedical Corp.
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 18 Jul 2023, 17:37.

Change

Previous filing in this sequence was filed on 25 Apr 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TLIS transaction Derivative

Stock option (right to buy)

Award

Transaction value: $0
Shares: +13,071
Change %
Price: $0.000000
Shares after: 13,071
Date: 17 Jul 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 13,071
Exercise price: $7.65
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25% of the shares underlying this option shall vest on the first annual anniversary of the vesting commencement date of April 21, 2023 and 1/48th of the shares underlying this option shall vest monthly thereafter over 36 months.